Global Non-24-hour Sleep-wake Disorder Treatment Market Growth (Status and Outlook) 2023-2029

Global Non-24-hour Sleep-wake Disorder Treatment Market Growth (Status and Outlook) 2023-2029

The global Non-24-hour Sleep-wake Disorder Treatment market size is projected to grow from US$ 469.6 million in 2022 to US$ 721.5 million in 2029; it is expected to grow at a CAGR of 6.3% from 2023 to 2029.

United States market for Non-24-hour Sleep-wake Disorder Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Non-24-hour Sleep-wake Disorder Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Non-24-hour Sleep-wake Disorder Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Non-24-hour Sleep-wake Disorder Treatment players cover Teva, Mylan, Nature’s Bounty, Otsuka Pharma (Pharmavite), Boiron, Miers Laboratories, Genexa, Homeocan and Clinigen Group, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Non-24-hour sleep-wake disorder (N24) is a circadian rhythm sleep disorder in which an individual's biological clock fails to synchronize to a 24-hour day. Instead of sleeping at roughly the same time every day, someone with N24 will typically find their sleep time gradually delaying by minutes to hours every day.

LPI (LP Information)' newest research report, the “Non-24-hour Sleep-wake Disorder Treatment Industry Forecast” looks at past sales and reviews total world Non-24-hour Sleep-wake Disorder Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Non-24-hour Sleep-wake Disorder Treatment sales for 2023 through 2029. With Non-24-hour Sleep-wake Disorder Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-24-hour Sleep-wake Disorder Treatment industry.

This Insight Report provides a comprehensive analysis of the global Non-24-hour Sleep-wake Disorder Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-24-hour Sleep-wake Disorder Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-24-hour Sleep-wake Disorder Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-24-hour Sleep-wake Disorder Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-24-hour Sleep-wake Disorder Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Non-24-hour Sleep-wake Disorder Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Prescription Drugs
OTC

Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Mylan
Nature’s Bounty
Otsuka Pharma (Pharmavite)
Boiron
Miers Laboratories
Genexa
Homeocan
Clinigen Group
Vanda Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.